Edition:
United States

Myriad Genetics Inc (MYGN.OQ)

MYGN.OQ on NASDAQ Stock Exchange Global Select Market

32.48USD
3:59pm EST
Change (% chg)

$-1.26 (-3.73%)
Prev Close
$33.74
Open
$33.50
Day's High
$33.52
Day's Low
$31.50
Volume
466,470
Avg. Vol
328,349
52-wk High
$37.30
52-wk Low
$15.15

Latest Key Developments (Source: Significant Developments)

Myriad Genetics posts Q1 adjusted earnings per share $0.26
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Myriad Genetics Inc :Myriad Genetics reports fiscal first-quarter 2018 financial results.Q1 adjusted earnings per share $0.26.Q1 GAAP earnings per share $1.15.Q1 revenue $190.2 million versus I/B/E/S view $183.4 million.Q1 earnings per share view $0.21 -- Thomson Reuters I/B/E/S.Myriad Genetics Inc sees ‍fiscal year 2018 revenue $750 million to $770 million​.Myriad Genetics Inc sees ‍fiscal year 2018 earnings per share $1.41-$1.46​.Myriad Genetics Inc sees ‍fiscal year 2018 adjusted earnings per share $1.00-$1.05​.Myriad Genetics Inc sees ‍fiscal second-quarter 2018 revenue $187 million to $189 million​.Myriad Genetics Inc sees ‍fiscal second-quarter 2018 earnings per share $0.08-$0.10; sees fiscal second-quarter 2018 adjusted earnings per share $0.22-$0.24​.FY2018 earnings per share view $1.03, revenue view $764.6 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $0.25, revenue view $189.9 million -- Thomson Reuters I/B/E/S.  Full Article

Myriad submits BRACAnalysis® CDx application for regulatory approval in Japan
Tuesday, 24 Oct 2017 07:05am EDT 

Oct 24 (Reuters) - Myriad Genetics Inc :Myriad submits BRACAnalysis® CDX application for regulatory approval in Japan for HER2- metastatic breast cancer.Myriad Genetics Inc - submitted BRACAnalysis CDX in Japan for review by PMDA and marketing approval by Ministry Of Health, Labor and Welfare​.Myriad Genetics Inc - ‍submitted marketing approval as a companion diagnostic to olaparib for use in HER2- metastatic breast cancer patients​.  Full Article

Myriad Genetics’s supplementary PMA for BRACAnalysis CDx accepted by FDA for review
Wednesday, 18 Oct 2017 07:00am EDT 

Oct 18 (Reuters) - Myriad Genetics Inc :Myriad’s BRACAnalysis CDx supplementary pma accepted by fda for review as a companion diagnostic for Lynparza (olaparib) in metastatic breast cancer.Myriad Genetics Inc - ‍Myriad expects FDA'S priority review process to conclude in fiscal third-quarter 2018​.  Full Article

Myriad Genetics Inc announces launch of riskScore
Tuesday, 5 Sep 2017 05:23pm EDT 

Sept 5 (Reuters) - Myriad Genetics Inc :Myriad Genetics Inc - September 5, co announced it has launched riskScore - SEC filing.  Full Article

EndoPredict receives positive coverage decisions from Medicare and Anthem
Thursday, 17 Aug 2017 04:15pm EDT 

Aug 17 (Reuters) - Myriad Genetics Inc :EndoPredict receives positive coverage decisions from Medicare and Anthem.Myriad Genetics Inc - ‍Palmetto GBA have announced positive coverage decisions for EndoPredict testing​.Myriad Genetics Inc - ‍Myriad will now have coverage for over 90 percent of breast cancer patients​.  Full Article

Myriad Genetics Q4 adjusted earnings per share $0.30
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Myriad Genetics Inc :Myriad Genetics reports fiscal fourth-quarter 2017 and fiscal full-year 2017 financial results.Q4 adjusted earnings per share $0.30.Q4 GAAP earnings per share $0.19.Q4 revenue $200.5 million versus I/B/E/S view $193.7 million.Q4 earnings per share view $0.26 -- Thomson Reuters I/B/E/S.Myriad Genetics Inc sees fiscal year 2018 revenue $750-$770 million.Myriad Genetics Inc sees fiscal year 2018 GAAP diluted earnings per share $0.37-$0.42.Myriad Genetics Inc sees fiscal year 2018 adjusted earnings per share $1.00-$1.05.Myriad Genetics Inc sees first-quarter 2018 revenue $181-$183 million.Myriad Genetics Inc sees first-quarter 2018 GAAP diluted earnings per share $0.05-$0.07.Myriad Genetics Inc sees first-quarter 2018 adjusted earnings per share $0.19-$0.21.Q1 earnings per share view $0.24, revenue view $191.8 million -- Thomson Reuters I/B/E/S.FY2018 earnings per share view $1.08, revenue view $789.1 million -- Thomson Reuters I/B/E/S.  Full Article

Myriad Genetics agree on new long-term relationship with UnitedHealthcare
Wednesday, 21 Jun 2017 09:19am EDT 

June 21 (Reuters) - Myriad Genetics Inc :Myriad genetics inc - on june 19, agreed on a new long-term relationship with unitedhealthcare - sec filing.Myriad genetics inc - new product coverage will be determined based on a member's benefit plan, additional terms of deal are not disclosed.Myriad genetics inc - relationship established pricing for its hereditary cancer tests, genesight, prolaris, vectra da and endopredict.  Full Article

Agena Bioscience announces expanded partnership with Assurex Health
Tuesday, 20 Jun 2017 08:13am EDT 

June 20 (Reuters) - Myriad Genetics Inc :Agena bioscience - assurex health, subsidiary of myriad genetics, has selected massarray system for streamlined laboratory set-up, sample processing of assurex health's genesight test.Agena bioscience - under new partnership, assurex health expects to significantly increase number of genesight test samples run on the massarray system.  Full Article

Myriad Genetics announces results from a large 2,000 patient clinical utility study of its myRisk Hereditary Cancer Test
Friday, 2 Jun 2017 07:05am EDT 

June 2 (Reuters) - Myriad Genetics Inc :Myriad Genetics Inc announces results from a large 2,000 patient clinical utility study of its myRisk Hereditary Cancer Test.Myriad Genetics - ‍key findings are that more than 50 percent of mutations identified were in patients who would not meet current testing guidelines​.Myriad Genetics-34 percent mutations identified in unexpected genes, confirming use of multi-gene panel testing to improve hereditary cancer-risk assessment.  Full Article

Myriad Genetics reports Q3 adj earnings per share $0.27
Tuesday, 2 May 2017 04:05pm EDT 

May 2 (Reuters) - Myriad Genetics Inc :Myriad Genetics reports fiscal third-quarter 2017 financial results.Q3 adjusted earnings per share $0.27.Q3 gaap earnings per share $0.06.Q3 revenue $196.9 million versus i/b/e/s view $189.1 million.Q3 earnings per share view $0.23 -- Thomson Reuters I/B/E/S.Myriad Genetics Inc sees fiscal year 2017 revenue in the range of $763 million to $765 million.Myriad Genetics Inc sees 2017 gaap earnings per share $0.23-$0.25.Myriad Genetics Inc sees 2017 non-gaap earnings per share $1.01-$1.03.Fy2017 earnings per share view $0.99, revenue view $751.5 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Myriad Genetics posts Q1 adjusted earnings per share $0.26

* Myriad Genetics reports fiscal first-quarter 2018 financial results